SCHEMBL20519396

SCHEMBL20519396

Cc1c(NC(=O)OC(C)(C)C)cncc1B(O)O

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 1/20 0.38
CYP17A1 P05093 3/20 0.36
ATR Q13535 1/20 0.36
BRD9 Q9H8M2 1/20 0.36
NFKB1 P19838 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
IDO1 P14902 1/20 0.36
METAP1 P53582 1/20 0.35
PRMT5 O14744 1/20 0.35
WDR77 Q9BQA1 1/20 0.35
RAB9A P51151 1/20 0.34
ELANE P08246 1/20 0.34
CTRB1 P17538 1/20 0.34
DRD2 P14416 1/20 0.33
LCK P06239 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17327940 0.81 CYP17A1 (0.44) NAMPTCYP17A1ATRBRD9IDO1
SCHEMBL6503172 0.81 NAMPT (0.39) NAMPTCYP17A1ATRBRD9IDO1
SCHEMBL29955026 0.79 NAMPT (0.46) NAMPTCYP17A1ATRMETAP1RAB9A
SCHEMBL1233405 0.79 NAMPT (0.46) NAMPTCYP17A1ATRMETAP1RAB9A
SCHEMBL1233798 0.79 NAMPT (0.46) NAMPTCYP17A1ATRMETAP1RAB9A
SCHEMBL29950993 0.79 NAMPT (0.46) NAMPTCYP17A1ATRMETAP1RAB9A
SCHEMBL21439216 0.78 RXFP1 (0.43) BRD9METAP1ELANECTRB1LCK
SCHEMBL23170196 0.76 P2RX3 (0.39) NAMPTCYP17A1ATRBRD9IDO1
SCHEMBL27365853 0.76 NAMPT (0.39) NAMPTCYP17A1ATRBRD9IDO1
SCHEMBL29955405 0.75 BRD9 (0.38) NAMPTCYP17A1ATRBRD9METAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3601284-B1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 HOFFMANN LA ROCHE (CH) 2023-12-27 EP disclosed
US-11034692-B1 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2021-06-15 US disclosed
US-11034692-B1 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2021-06-15 US disclosed
EP-3601284-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 H. Hoffnabb-La Roche Ag (CH) 2020-02-05 EP disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 US disclosed
US-10407424-B2 Naphthyridines as inhibitors of HPK1 GENENTECH, INC. (US) 2019-09-10 US disclosed
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 US disclosed
WO-2018183956-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2018-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407424-B2 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 NAMPT 821/4885CYP17A1 3238/4885ATR 4152/4885
US-20180282328-A1 NAPHTHYRIDINES AS INHIBITORS OF HPK1 NEK1, NEK5, NEK11 NAMPT 821/4885CYP17A1 3238/4885ATR 4152/4885
US-11034692-B1 Naphthyridines as inhibitors of HPK1 NEK1, NEK5, NEK11 NAMPT 821/4885CYP17A1 3238/4885ATR 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.